Current Report Filing (8-k)
July 25 2022 - 9:02AM
Edgar (US Regulatory)
0001401914
false
0001401914
2022-07-25
2022-07-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported): July 25, 2022
DARÉ BIOSCIENCE,
INC.
(Exact name of registrant
as specified in its charter)
Delaware |
|
001-36395 |
|
20-4139823 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
3655 Nobel Drive,
Suite 260
San Diego, CA 92122
(Address of Principal
Executive Offices and Zip Code)
Registrant’s telephone
number, including area code: (858) 926-7655
Not Applicable
(Former name or former
address, if changed since last report.)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock |
|
DARE |
|
Nasdaq
Capital Market |
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Exhibit 99.1 to this
report is a presentation about Daré Bioscience, Inc. (“Daré”) and its business dated July 25, 2022, which is
incorporated herein by reference. Daré intends to use the presentation and its contents in various meetings with investors, securities
analysts and others, commencing on July 25, 2022.
Item
9.01 |
Financial
Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
DARÉ
BIOSCIENCE, INC. |
|
|
|
Dated:
July 25, 2022 |
By: |
/s/
Sabrina Martucci Johnson |
|
Name: |
Sabrina
Martucci Johnson |
|
Title: |
President
and Chief Executive Officer |
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Aug 2023 to Aug 2024